scholarly journals P-320 Genetic testing for microsatellite instability and KRAS mutation in stage IV colorectal cancer: Trends and outcomes from the National Cancer Database

2020 ◽  
Vol 31 ◽  
pp. S193-S194
Author(s):  
J. Uhlig ◽  
S. Stein ◽  
M. Cecchini ◽  
H. Kim
Keyword(s):  
Colorectal Cancer ◽  
Genetic Testing ◽  
Microsatellite Instability ◽  
Kras Mutation ◽  
Stage Iv ◽  
National Cancer Database ◽  
Stage Iv Colorectal Cancer ◽  
Cancer Trends

scholarly journals Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database

2021 ◽  
Vol 19 (3) ◽  
pp. 307-318
Author(s):  
Johannes Uhlig ◽  
Michael Cecchini ◽  
Amar Sheth ◽  
Stacey Stein ◽  
Jill Lacy ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Stage Iv ◽  
Cox Proportional Hazards ◽  
National Cancer Database ◽  
Wild Type ◽  
Rectosigmoid Junction ◽  
Us States ◽  
Stage Iv Colorectal Cancer ◽  
South Central

Background: This study sought to assess microsatellite and KRAS status, prevalence, and impact on outcome in stage IV colorectal cancer (CRC). Materials and Methods: The 2010 to 2016 US National Cancer Database was queried for adult patients with stage IV CRC. Prevalence of microsatellite status (microsatellite instability–high [MSI-H] or microsatellite stable [MSS]) and KRAS status (KRAS mutation or wild-type) of the primary CRC was assessed. Overall survival (OS) was evaluated using multivariable Cox proportional hazards models in patients with complete data on both microsatellite and KRAS status and information on follow-up. Results: Information on microsatellite and KRAS status was available for 10,844 and 25,712 patients, respectively, and OS data were available for 5,904 patients. The overall prevalence of MSI-H status and KRAS mutation was 3.1% and 42.4%, respectively. Prevalence of MSI-H ranged between 1.6% (rectosigmoid junction) and 5.2% (transverse colon), and between 34.7% (sigmoid colon) and 58.2% (cecum) for KRAS mutation. MSI-H rates were highest in East North Central US states (4.1%), and KRAS mutation rates were highest in West South Central US states (44.1%). Multivariable analyses revealed longer OS for patients with KRAS wild-type versus mutation status (hazard ratio [HR], 0.91; 95% CI, 0.85–0.97; P=.004), those with MSS versus MSI-H status (HR, 0.75; 95% CI, 0.62–0.9; P=.003), and those with left-sided versus right-sided CRC (multivariable HR, 0.65; 95% CI, 0.6–0.7; P<.001). The effect of KRAS mutation further varied with CRC site and microsatellite status (P=.002 for interaction). Conclusions: Depending on the primary site and US geography, stage IV CRC shows distinct mutational behavior. KRAS mutation, MSI-H, and primary CRC sidedness independently affect OS and interact with distinct prognostic profiles. Generically classifying adenocarcinomas at different sites as CRC might deprecate this diversity.

scholarly journals Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer

2014 ◽  
Vol 39 (6) ◽  
pp. 1261-1266 ◽  
Author(s):  
Michael H. Rosenthal ◽  
Kyung Won Kim ◽  
Charles S. Fuchs ◽  
Jeffrey A. Meyerhardt ◽  
Nikhil H. Ramaiya
Keyword(s):  
Colorectal Cancer ◽  
Kras Mutation ◽  
Stage Iv ◽  
Mutation Status ◽  
Stage Iv Colorectal Cancer ◽  
Kras Mutation Status

scholarly journals Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor

2017 ◽  
Vol 37 (1) ◽  
pp. 239-248 ◽  
Author(s):  
KENJI FUJIYOSHI ◽  
GOU YAMAMOTO ◽  
TAKASHI TAKENOYA ◽  
AKEMI TAKAHASHI ◽  
YOSHIKO ARAI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Microsatellite Instability ◽  
High Frequency ◽  
Stage Iv ◽  
Metastatic Pattern ◽  
Stage Iv Colorectal Cancer

Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16052-e16052
Author(s):  
Johannes Uhlig ◽  
Michael Cecchini ◽  
Stacey Stein ◽  
Jill Lacy ◽  
Kevin Kim
Keyword(s):  
Overall Survival ◽  
Microsatellite Instability ◽  
Kras Mutation ◽  
Proportional Hazards ◽  
A Priori ◽  
Stage Iv ◽  
Cox Proportional Hazards ◽  
Treatment Center ◽  
National Cancer Database ◽  
Kras Status

e16052 Background: To assess microsatellite instability (MSI) and KRAS mutation prevalence, discrepancies and their impact on outcome in AJCC stage IV colorectal adenocarcinoma (colorectal cancer; CRC). Methods: The 2010-2016 United States National Cancer Database was queried for stage IV CRC patients > 18yo and information on MSI and KRAS mutation. Microsatellite status was stratified as stable microsatellites (MSS, including low instability) and microsatellite instability high (MSI-H). KRAS status was stratified as mutation and wildtype. Prevalence and discrepancies were evaluated according to patient demographics, US geography and CRC factors. Overall survival (OS) was assessed using Cox proportional hazards models adjusting for age, gender, race, comorbidities, metastatic burden, CRC treatment, treatment center type, and year of CRC diagnosis. A priori, a statistical interaction test between microsatellite status, KRAS status and primary CRC site was planned. Results: Microsatellite/KRAS status was available for n = 10,844/n = 25,712 patients, respectively. OS was assessed in n = 5,904 patients with data on both microsatellite and KRAS status, and follow-up. Overall prevalence of MSI-H was 3.1% and KRAS mutation 42.4%. Microsatellite and KRAS status varied according to primary CR site, as presented in Table. Further variation was evident according to US-geography, with MSI-H rates ranging from 1.6% to 4.1%, and KRAS mutation rates ranging from 41.1% to 44%. On multivariable analyses, longer OS was observed in patients with KRAS wildtype versus mutation (HR = 0.91, 95% CI: 0.85-0.97 p = 0.004), MSS versus MSI-H (HR = 0.75, 95% CI: 0.62-0.9, p = 0.003), and left-sided versus right-sided CRC (HR = 0.65, 95% CI: 0.6-0.7, p < 0.001). The effect of KRAS mutation further varied with CRC site and microsatellite status (interaction p = 0.002). Conclusions: Depending on its primary site and US geography, stage IV CRC shows distinct mutational behavior. KRAS mutation, MSI-H, MSI-H and primary CRC sidedness independently affect overall survival and interact with distinct prognostic profiles. Generically classifying adenocarcinomas of different site as “CRC” might deprecate this diversity. [Table: see text]

Factors impacting the diagnosis of stage IV colorectal cancer: A National Cancer Database (NCDB) analysis.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e17605-e17605
Author(s):  
Alison Emily Brandeis ◽  
Gaurav Goyal ◽  
Peter T. Silberstein
Keyword(s):  
Colorectal Cancer ◽  
Stage Iv ◽  
National Cancer Database ◽  
Stage Iv Colorectal Cancer

scholarly journals Prognostic factors of survival in stage IV colorectal cancer with synchronous liver metastasis: Negative effect of the KRAS mutation

2021 ◽  
Vol 14 (5) ◽  
Author(s):  
Manuel Díez‑alonso ◽  
Fernando Mendoza‑Moreno ◽  
Laura Jiménez‑Alvarez ◽  
Oscar Nuñez ◽  
Alma Blazquez‑Martín ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Liver Metastasis ◽  
Kras Mutation ◽  
Stage Iv ◽  
Synchronous Liver Metastasis ◽  
Stage Iv Colorectal Cancer ◽  
Negative Effect

Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer

2017 ◽  
Vol 42 (6) ◽  
pp. 1621-1626 ◽  
Author(s):  
Arthur Cho ◽  
Kwanhyeong Jo ◽  
Sang Hyun Hwang ◽  
Narae Lee ◽  
Minkyu Jung ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Kras Mutation ◽  
Stage Iv ◽  
Fdg Uptake ◽  
Stage Iv Colorectal Cancer ◽  
18F Fdg

INVESTIGATION KRAS MUTATION IN CIRCULATION TUMOR DNA IN DIFFERENT STAGES OF COLORECTAL CANCER

2019 ◽  
Vol 65 (5) ◽  
pp. 701-707
Author(s):  
Vitaliy Shubin ◽  
Yuriy Shelygin ◽  
Sergey Achkasov ◽  
Yevgeniy Rybakov ◽  
Aleksey Ponomarenko ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasma Volume ◽  
Kras Mutation ◽  
Stage Iv ◽  
Circulating Tumor Dna ◽  
Stage Ii ◽  
Kras Gene ◽  
Kras Mutations ◽  
Droplet Pcr ◽  
Tumor Dna

To determine mutations in the plasma KRAS gene in patients with colorectal cancer was the aim of this study. The material was obtained from 44 patients with colorectal cancer of different stages (T1-4N0-2bM0-1c). Plasma for the presence of KRAS gene mutation in circulating tumor DNA was investigated using digital droplet polymerase chain reaction (PCR). KRAS mutations in circulating tumor DNA isolated from 1 ml of plasma were detected in 13 (30%) patients with cancer of different stages. Of these, with stage II, there were 3 patients, with III - 5 and with IV - 5. Patients who did not have mutations in 1 ml of plasma were analyzed for mutations of KRAS in circulating tumor DNA isolated from 3 ml of plasma. Five more patients with KRAS mutations were found with II and III stages. The highest concentrations of circulating tumor DNA with KRAS mutation were found in patients with stage IV. The increase in plasma volume to 3 ml did not lead to the identification of mutations in I stage. This study showed that digital droplet PCR allows identification of circulating tumor DNA with the KRAS mutations in patients with stage II-IV of colon cancer. The results can be used to determine the degree of aggressiveness of the tumor at different stages of the disease, but not the 1st, and it is recommended to use a plasma volume of at least 3 ml.

Sign in / Sign up

Export Citation Format

Share Document